ArticleEye (London, England)2026
Ocular surface and meibomian gland changes following repeated exposure to 5% povidone-iodine during intravitreal injections.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the impact of repeated exposure to 5 percent povidone iodine on meibomian gland atrophy in eyes receiving intravitreal injections.
methodsPatients undergoing intravitreal injections with a standardised protocol that included 5% povidone-iodine instillation in one eye were prospectively enroled. Eligible patients had received their last injection within the previous 12 weeks. Patients were stratified according to the number of prior injections. Those with systemic conditions or medications affecting ocular surface parameters were excluded. Assessments included Keratograph 5 M meibography, slit lamp examination, and Schirmer testing at baseline, one hour, and seven days after injection. Meibomian gland atrophy was quantified using ImageJ software. Statistical analysis included repeated-measures ANOVA, regression modelling, and interobserver agreement.
resultsA total of 143 patients with a mean age of 69 years were included. Age-related macular degeneration was the predominant diagnosis, and treat and extend was the most common protocol. In the study eye, tear meniscus height, bulbar hyperaemia, and Schirmer scores increased, while tear breakup time decreased at one hour post-injection. These changes were most evident in patients with fewer than five or more than thirteen prior injections and resolved by day seven. Meibography revealed reduced gland atrophy, especially in the inferior eyelid. Regression analysis showed a small but significant inverse association between injection number and gland atrophy.
conclusionsPatients with more intravitreal injections and greater exposure to 5% povidone-iodine showed less meibomian gland atrophy, particularly in the inferior eyelid, along with improved ocular surface parameters.
Identifiers
42557420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.